Literature DB >> 23704203

Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?

F Buchegger1, J-P Mach2, O W Press3, A Bischof Delaloye4, S M Larson5, J O Prior6, N Ketterer7.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23704203      PMCID： PMC6267862          DOI： 10.1093/annonc/mdt198

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  10 in total

1.  Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission.

Authors:  Franz Buchegger; Cristian Antonescu; Claudine Helg; Marek Kosinski; John O Prior; Angelika Bischof Delaloye; Oliver W Press; Nicolas Ketterer
Journal:  J Nucl Med       Date:  2011-05-13       Impact factor: 10.057

2.  Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.

Authors:  Suresh Veeramani; Siao-Yi Wang; Christopher Dahle; Sue Blackwell; Laura Jacobus; Tina Knutson; Anna Button; Brian K Link; George J Weiner
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

3.  131I-tositumomab therapy as initial treatment for follicular lymphoma.

Authors:  Mark S Kaminski; Melissa Tuck; Judith Estes; Arne Kolstad; Charles W Ross; Kenneth Zasadny; Denise Regan; Paul Kison; Susan Fisher; Stewart Kroll; Richard L Wahl
Journal:  N Engl J Med       Date:  2005-02-03       Impact factor: 91.245

4.  Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.

Authors:  Giovanni Martinelli; Shu-Fang Hsu Schmitz; Urs Utiger; Thomas Cerny; Urs Hess; Simona Bassi; Emmie Okkinga; Roger Stupp; Rolf Stahel; Marc Heizmann; Daniel Vorobiof; Andreas Lohri; Pierre-Yves Dietrich; Emanuele Zucca; Michele Ghielmini
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

5.  Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.

Authors:  Lindsey Goff; Karin Summers; Sameena Iqbal; Jens Kuhlmann; Michael Kunz; Tom Louton; Anton Hagenbeek; Franck Morschhauser; Barbara Putz; Andrew Lister; Ama Rohatiner
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

6.  ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

Authors:  M Ghielmini; U Vitolo; E Kimby; S Montoto; J Walewski; M Pfreundschuh; M Federico; P Hoskin; C McNamara; F Caligaris-Cappio; S Stilgenbauer; R Marcus; M Trneny; P Dreger; E Montserrat; M Dreyling
Journal:  Ann Oncol       Date:  2012-11-21       Impact factor: 32.976

7.  Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

Authors:  Issa F Khouri; Rima M Saliba; William D Erwin; Barry I Samuels; Martin Korbling; L Jeffrey Medeiros; Rosamar Valverde; Amin M Alousi; Paolo Anderlini; Qaiser Bashir; Stefan Ciurea; Alison M Gulbis; Marcos de Lima; Chitra Hosing; Partow Kebriaei; Uday R Popat; Nathan Fowler; Sattva S Neelapu; Felipe Samaniego; Richard E Champlin; Homer A Macapinlac
Journal:  Blood       Date:  2012-05-14       Impact factor: 22.113

8.  Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

Authors:  Oliver W Press; Joseph M Unger; Lisa M Rimsza; Jonathan W Friedberg; Michael LeBlanc; Myron S Czuczman; Mark Kaminski; Rita M Braziel; Catherine Spier; Ajay K Gopal; David G Maloney; Bruce D Cheson; Shaker R Dakhil; Thomas P Miller; Richard I Fisher
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 50.717

9.  Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.

Authors:  Simon J Dovedi; Monique H M Melis; Robert W Wilkinson; Amy L Adlard; Ian J Stratford; Jamie Honeychurch; Timothy M Illidge
Journal:  Blood       Date:  2012-10-18       Impact factor: 22.113

10.  Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets.

Authors:  A Lanzavecchia; S Abrignani; D Scheidegger; R Obrist; B Dörken; G Moldenhauer
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307
  10 in total
  1 in total

Review 1.  Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.

Authors:  Franz Buchegger; Steven M Larson; Jean-Pierre Mach; Yves Chalandon; Pierre-Yves Dietrich; Anne Cairoli; John O Prior; Pedro Romero; Daniel E Speiser
Journal:  Clin Dev Immunol       Date:  2013-11-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.